查找临床试验
已按「皮肌炎」检索，对应国际通用词 dermatomyositis
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
United States、Argentina、Bulgaria、China、Hungary 等 12 国
年龄 18 Years – 不限
Pfizer
Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response Evaluation
China
年龄 18 Years – 80 Years
Peking Union Medical College Hospital
Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)
China
年龄 5 Years – 不限
Chongqing Precision Biotech Co., Ltd
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
United States、Australia、Austria、Bulgaria、Canada 等 12 国
年龄 18 Years – 85 Years
Chugai Pharmaceutical
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
China
年龄 5 Years – 17 Years
Chongqing Precision Biotech Co., Ltd
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 75 Years
AstraZeneca
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
China
年龄 18 Years – 70 Years
The First Affiliated Hospital with Nanjing Medical University
Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
China
年龄 5 Years – 不限
Chongqing Precision Biotech Co., Ltd
RCT of Tocilizumab for Anti-MDA5+DM
China
年龄 18 Years – 65 Years
Peking Union Medical College Hospital
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
United States、Argentina、Bulgaria、China、France 等 12 国
年龄 18 Years – 不限
Pfizer
Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy Trial
China
年龄 18 Years – 75 Years
Li Shiyue
Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung Disease
China
年龄 18 Years – 100 Years
Chinese PLA General Hospital